Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM6 | O15303 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ATR | Q13535 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16244892 | 0.98 | GRM6 (0.36) | GRM6CYP2C9CYP2C19NPSR1DGAT1 | |
| SCHEMBL522356 | 0.91 | GRM6 (0.36) | GRM6CYP2C9CYP2C19NPSR1DGAT1 | |
| SCHEMBL28467235 | 0.85 | CA12 (0.40) | GRM6CYP2C9CYP2C19NPSR1CA12 | |
| SCHEMBL10073234 | 0.76 | KMT2A (0.49) | GRM6CYP2C9CYP2C19NPSR1CA12 | |
| SCHEMBL11757930 | 0.76 | KDM4E (0.32) | — | |
| SCHEMBL522898 | 0.75 | TSHR (0.37) | GRM6CYP2C9CYP2C19NPSR1DGAT1 | |
| SCHEMBL6580237 | 0.75 | GRM6 (0.40) | GRM6CYP2C9CYP2C19NPSR1DGAT1 | |
| SCHEMBL5712646 | 0.75 | GRM6 (0.44) | GRM6CYP2C9CYP2C19NPSR1DGAT1 | |
| SCHEMBL28569434 | 0.74 | HSP90AA1 (0.39) | GRM6CYP2C9CYP2C19NPSR1CA12 | |
| SCHEMBL22032165 | 0.74 | NR1H4 (0.39) | GRM6CYP2C9CYP2C19NPSR1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2415741-A1 | METHOD FOR PRODUCING ALCOHOL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20120029195-A1 | METHOD FOR PRODUCING ALCOHOL COMPOUND AND CATALYST THEREFOR | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-02-02 | — | — | US | disclosed |
| US-20120010417-A1 | METHOD FOR PRODUCING ALCOHOL COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-01-12 | — | — | US | disclosed |
| US-7973201-B2 | Process for production of halogen-substituted benzenedimethanol | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-07-05 | — | — | US | disclosed |
| EP-1783108-B1 | METHOD FOR PRODUCING HALOGEN-SUBSTITUTED BENZENEDIMETHANOL | SUMITOMO CHEMICAL CO (JP) | 2010-12-22 | — | — | EP | disclosed |
| US-20100174122-A1 | PROCESS FOR PRODUCTION OF HALOGEN-SUBSTITUTED BENZENEDIMETHANOL | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-07-08 | — | — | US | disclosed |
| US-7678947-B2 | reacting a halogen-substituted terephthalic acid diester with a borohydride compound in the presence of an alcohol and a solvent | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-03-16 | — | — | US | disclosed |
| EP-2033944-A1 | PROCESS FOR PRODUCTION OF HALOGEN-SUBSTITUTED BENZENEDIMETHANOL | Sumitomo Chemical Company, Limited (JP) | 2009-03-11 | — | — | EP | disclosed |
| US-20070213570-A1 | reacting a halogen-substituted terephthalic acid diester with a borohydride compound in the presence of an alcohol and a solvent | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-09-13 | — | — | US | disclosed |
| EP-1783108-A1 | METHOD FOR PRODUCING HALOGEN-SUBSTITUTED BENZENEDIMETHANOL | Sumitomo Chemical Company, Limited (JP) | 2007-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010417-A1 | METHOD FOR PRODUCING ALCOHOL COMPOUND | ADH1A, ADH1C, ADH5 | GRM6 817/4885CYP2C9 175/4885CYP2C19 366/4885 |
| US-20070213570-A1 | reacting a halogen-substituted terephthalic acid diester with a borohydride compound in the presence of an alcohol and a solvent | ADH1A, ADH1C, CYP4A11 | GRM6 3461/4885CYP2C9 564/4885CYP2C19 638/4885 |
| US-20100174122-A1 | PROCESS FOR PRODUCTION OF HALOGEN-SUBSTITUTED BENZENEDIMETHANOL | HRH4, HAX1, XDH | GRM6 3322/4885CYP2C9 285/4885CYP2C19 373/4885 |
| US-20120029195-A1 | METHOD FOR PRODUCING ALCOHOL COMPOUND AND CATALYST THEREFOR | ADH1A, ADH1C, ADH5 | GRM6 2369/4885CYP2C9 400/4885CYP2C19 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.